A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting
ConclusionsAs the first analysis evaluating the economic outcomes of enoxaparin in patients undergoing general non-orthopedic surgery, this study suggests that thromboprophylaxis with enoxaparin is highly cost-effective compared with no prevention in patients with Caprini risk score ≥ 3.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: China Health | Drugs & Pharmacology | Lovenox | Orthopaedics | Pulmonary Thromboembolism | Study | Thrombosis